HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?-Reference-Cited by-同舟云学术

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?

Published:2007-01-30 Issue:4 Volume:96 Page:654-659
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Vincent-Salomon A,Pierga J-Y,Couturier J,d'Enghien C D,Nos C,Sigal-Zafrani B,Lae M,Fréneaux P,Diéras V,Thiéry J-P,Sastre-Garau X

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603584.pdf

Reference35 articles.

1. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G (2004) Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534–8540

2. Azoulay S, Lae M, Freneaux P, Merle S, Al Ghuzlan A, Chnecker C, Rosty C, Klijanienko J, Sigal-Zafrani B, Salmon R, Fourquet A, Sastre-Garau X, Vincent-Salomon A (2005) KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol 18: 1623–1631

3. Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Atman DG (1988) An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58: 448–452

4. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, van de Vijver M (2003) Current perspectives on HER2 testing: a review of national testing guidelines. Modern Pathol 16: 173–182

5. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RCS, BM, Wunder E, Marolleau J-P, Garcia J, Pantel K (1999) Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1: 377–388

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists;Histopathology;2024-07-08

2. Features of tumor heterogeneity in regional metastasis of breast cancer;Kazan medical journal;2021-10-13

3. Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study;Cancer Medicine;2021-10-06

4. EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma;Scientific Reports;2020-05-14

5. Automated detection of the HER2 gene amplification status in Fluorescence in situ hybridization images for the diagnostics of cancer tissues;Scientific Reports;2019-06-03